Table 3 Antimicrobial susceptibility of separate CRE isolates
Antimicrobial Agent | Susceptible strains, % | ||
|---|---|---|---|
Klebsiella pneumonia | Escherichia coli | Enterobacter cloacae | |
Aminoglycocides | 60.4% | 58.7% | 77.6% |
Amikacin | 75.0% | 71.0% | 94.1% |
Tobramycin | 56.2% | 50.0% | 62.1% |
Gentamicin | 50.0% | 55.2% | 76.5% |
Cephalosporin | 3.1% | 5.1% | 29.4% |
Cefepime | 6.2% | 10.5% | 52.9% |
Ceftazidime | 0 | 0 | 5.9% |
Tigecycline | 81.3% | 65.8% | 100% |
Fluoroquinolone | 62.5% | 26.3% | 91.2% |
Ciprofloxacin | 68.8% | 26.3% | 94.1% |
Levofloxacin | 56.3% | 26.3% | 88.2% |
Carbapenem | 12.5% | 18.4% | 25.5% |
Imipenem | 12.5% | 23.7% | 35.3% |
Meropenem | 18.8% | 26.3% | 29.4% |
Ertapenem | 6.2% | 5.3% | 11.7% |
Piperacillin | 6.2% | 5.3% | 14.7% |
Piperacillin/tazobactam | 6.2% | 5.3% | 23.5% |
Piperacillin | 6.2% | 5.3% | 5.9% |